Amanta Healthcare Limited
163.07
INR
-1.81
(-1.10%)
Amanta Healthcare Limited
NSE:AMANTA
(National Stock Exchange of India)
Recent
price
163.07
P/E
ratio
38.96
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Amanta Healthcare Limited is an India-based pharmaceutical company that specializes in the development, manufacturing, and marketing of sterile liquid parenterals and healthcare formulations. The company utilizes advanced packaging and production technologies, including Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), to produce sterile solutions for hospital, critical care, pediatric, and general therapeutic use. Its core product portfolio encompasses Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) across multiple therapeutic categories: fluid therapy solutions, including normal saline, dextrose, dextrose with sodium chloride, and Ringers lactate; proprietary SteriPort infusion systems featuring a two-port, self-collapsible, and air-vent-free closure design; respiratory care formulations, such as sterile respules and inhalation solutions; ophthalmic preparations, including sterile eye drops and ocular lubricants; anti-infective, anti-protozoal, and anti-fungal injectables; sterile diluents and water for injection; and medical devices comprising sterile irrigation solutions. In addition to its branded generic formulations, the company provides contract manufacturing and product partnering services to domestic and multinational pharmaceutical enterprises. Founded in 1994 and headquartered in Ahmedabad, Gujarat, India, Amanta Healthcare operates a WHO-GMP and ISO-certified manufacturing facility in Hariyala, Kheda district, Gujarat. The company distributes its products across a nationwide network in India and exports sterile formulations to more than 20 countries across Asia, Africa, Latin America, and the Middle East. In recent developments, Amanta Healthcare completed its Initial Public Offering (IPO) in September 2025, listing its equity shares on the National Stock Exchange of India (NSE: AMANTA) and the Bombay Stock Exchange (BSE) to raise 126 crore INR in fresh equity capital. The company is utilizing the issue proceeds to fund capital expenditure at its Hariyala facility, including the construction and equipment procurement for a new high-speed SteriPort manufacturing line and a dedicated Small Volume Parenterals (SVP) line to expand production capacity and support domestic and export market growth.